Dr. Neil Maresky

Psyence Biomedical Ltd. (NASDAQ:PBM) has successfully obtained an extension from the Nasdaq Hearings Panel, giving the company until December 31, 2024, to meet the exchange's continued listing requirements. The decision, reached after a hearing on October 31, allows the company to remain listed...

Psyence Biomedical Ltd. (NASDAQ:PBM), a biotechnology company focused on creating natural psychedelic-based solutions to address mental health challenges, has issued an update to shareholders, highlighting significant recent developments and upcoming milestones. The company has initiated a Phase...

UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Psyence Group Inc. (OTCQB: PSYGF)’s application to assess the efficacy and safety of psilocybin-assisted psychotherapy compared to psychotherapy alone for treating adjustment disorder following an incurable...